Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what additional funding his Department will allocate to the NHS to fund the expansion of the PrEP Impact trial.
Answered by Seema Kennedy
Following my Rt. hon. Friend the Secretary of State for Health and Social Care’s announcement on 30 January that the Pre-Exposure Prophylaxis (PrEP) Impact Trial would be expanded to 26,000 people, NHS England has committed to fund the PrEP drug and research costs of these additional places, in line with current arrangements.
Local authority and clinic participation in the trial is on a voluntary basis. Participation costs of local authorities are met from existing resource allocations.
The 36 month PrEP Impact Trial is scheduled to continue until autumn 2020. Work is underway to prepare for a seamless transition from the PrEP trial to future commissioning arrangements, which includes consideration of funding options.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the level of vulnerability of NHS Microsoft operating systems to cyber attack.
Answered by Jackie Doyle-Price
We are supporting National Health Service organisations to upgrade their existing Microsoft Windows operating systems, allowing them to reduce potential vulnerabilities and increase cyber resilience.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 December to Question 198332 on Sickle Cell Diseases: Prescriptions, what assessment he has made of the effect on BAME patients of his policy not to include sickle cell anaemia in the list of conditions for which a medical exemption certificate can be obtained.
Answered by Seema Kennedy
The Department has made no assessment. This is because there are extensive arrangements in place to ensure that people can access affordable prescriptions. To support those with the greatest need who do not qualify for an exemption, prescription prepayment certificates are available.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the reduction in Category M prices and the single activity fee on the financial sustainability of community pharmacies.
Answered by Steve Brine
The overall funding for the community pharmacy contractual framework (CPCF) has not been reduced since 2017/18 and remains at £2.592 billion for 2018/19. The Department ensures delivery of this amount by adjusting the fees paid for services and the reimbursement paid for products throughout the year. Where there is over or under payment we make appropriate adjustment to either fees or product reimbursement (typically those in Category M) to address the difference. The impact assessment for the current CPCF funding is at the following link:
https://www.gov.uk/government/publications/community-pharmacy-reforms
The current recovery of excess medicine margin at £10 million per month, as agreed by the Pharmaceutical Services Negotiating Committee, ceases at the end of March 2019.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of changes to the market forces factor on future funding for NHS Trust and Clinical Commissioning Groups in London.
Answered by Stephen Hammond
NHS England is responsible for decisions on the weighted capitation formula used to allocate resources between clinical commissioning group (CCGs). NHS England take advice from the Advisory Committee on Resource Allocation, a group of academics and other experts. This process is independent of Government.
The CCG allocation formula takes account of unavoidable cost differences between areas by applying the Market Forces Factor (MFF) to all services except for prescribing.
The MFF has not been updated in nearly ten years so it was right that this has been reviewed as part of the changes made in the Long Term Plan. NHS England and Improvement are responsible for updating the methodology and underlying data used to calculate the MFF.
The proposed changes would result in changes in income and allocations for some providers and commissioners. Changes would be implemented over five years to phase the impact on providers.
My Rt. hon. Friend the Secretary of State for Health and Social Care will write to the hon. Member shortly.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to his oral contribution of 7 January 2019, Official Report, column 84, on NHS Long Term Plan, when he plans to write to the hon. Member for Greenwich and Woolwich with further details of the effect of changes to the market forces factor on funding for NHS Trusts in London to be allocated as part of the Plan.
Answered by Stephen Hammond
NHS England is responsible for decisions on the weighted capitation formula used to allocate resources between clinical commissioning group (CCGs). NHS England take advice from the Advisory Committee on Resource Allocation, a group of academics and other experts. This process is independent of Government.
The CCG allocation formula takes account of unavoidable cost differences between areas by applying the Market Forces Factor (MFF) to all services except for prescribing.
The MFF has not been updated in nearly ten years so it was right that this has been reviewed as part of the changes made in the Long Term Plan. NHS England and Improvement are responsible for updating the methodology and underlying data used to calculate the MFF.
The proposed changes would result in changes in income and allocations for some providers and commissioners. Changes would be implemented over five years to phase the impact on providers.
My Rt. hon. Friend the Secretary of State for Health and Social Care will write to the hon. Member shortly.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many contracts the Medicines and Healthcare Products Regulatory Agency has secured with the European Medicines Agency to carry out authorisation processes in each of the past five years.
Answered by Jackie Doyle-Price
The number of contracts secured by the Medicines and Healthcare products Regulatory Agency (MHRA) with the European Medicines Agency (EMA) in each of past five years is shown in the following table:
Financial year | Number of contracts |
2013/14 | 35 |
2014/15 | 27 |
2015/16 | 35 |
2016/17 | 41 |
2017/18 | 11 |
The information included in the table is based on the EMA Committee on Human Medicinal Products (CHMP) rapporteurships allocated to the MHRA for assessment of new marketing authorisation applications.
The proportion of the income of the MHRA that came from the EMA in each of the past five years is shown in the following table:
Financial year | Proportion of income |
2013/14 | 6% |
2014/15 | 6% |
2015/16 | 6% |
2016/17 | 9% |
2017/18 | 8% |
The source of the information is the MHRA’s Annual Report and Accounts for each of the past five years.
The number of bids submitted by the MHRA to carry out authorisations processes for the EMA based on the number of bids for CHMP rapporteurship for new marketing authorisation applications and the number of rapporteurships awarded in the last three financial years is shown in the following table:
Financial year | Number of bids submitted | Number of rapporteurships awarded |
2015/16 | 86 | 35 |
2016/17 | 87 | 41 |
2017/18 | 66 | 11 |
Metrics for bids submitted prior to this time have not been recorded.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of the income of the Medicines and Healthcare Products Regulatory Agency came from the European Medicines Agency in each of the past five years.
Answered by Jackie Doyle-Price
The number of contracts secured by the Medicines and Healthcare products Regulatory Agency (MHRA) with the European Medicines Agency (EMA) in each of past five years is shown in the following table:
Financial year | Number of contracts |
2013/14 | 35 |
2014/15 | 27 |
2015/16 | 35 |
2016/17 | 41 |
2017/18 | 11 |
The information included in the table is based on the EMA Committee on Human Medicinal Products (CHMP) rapporteurships allocated to the MHRA for assessment of new marketing authorisation applications.
The proportion of the income of the MHRA that came from the EMA in each of the past five years is shown in the following table:
Financial year | Proportion of income |
2013/14 | 6% |
2014/15 | 6% |
2015/16 | 6% |
2016/17 | 9% |
2017/18 | 8% |
The source of the information is the MHRA’s Annual Report and Accounts for each of the past five years.
The number of bids submitted by the MHRA to carry out authorisations processes for the EMA based on the number of bids for CHMP rapporteurship for new marketing authorisation applications and the number of rapporteurships awarded in the last three financial years is shown in the following table:
Financial year | Number of bids submitted | Number of rapporteurships awarded |
2015/16 | 86 | 35 |
2016/17 | 87 | 41 |
2017/18 | 66 | 11 |
Metrics for bids submitted prior to this time have not been recorded.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many contracts the Medicines and Healthcare Products Regulatory Agency bid for to carry out authorisation processes for the European Medicines Agency in each of the past five years; and how many of those bids were successful.
Answered by Jackie Doyle-Price
The number of contracts secured by the Medicines and Healthcare products Regulatory Agency (MHRA) with the European Medicines Agency (EMA) in each of past five years is shown in the following table:
Financial year | Number of contracts |
2013/14 | 35 |
2014/15 | 27 |
2015/16 | 35 |
2016/17 | 41 |
2017/18 | 11 |
The information included in the table is based on the EMA Committee on Human Medicinal Products (CHMP) rapporteurships allocated to the MHRA for assessment of new marketing authorisation applications.
The proportion of the income of the MHRA that came from the EMA in each of the past five years is shown in the following table:
Financial year | Proportion of income |
2013/14 | 6% |
2014/15 | 6% |
2015/16 | 6% |
2016/17 | 9% |
2017/18 | 8% |
The source of the information is the MHRA’s Annual Report and Accounts for each of the past five years.
The number of bids submitted by the MHRA to carry out authorisations processes for the EMA based on the number of bids for CHMP rapporteurship for new marketing authorisation applications and the number of rapporteurships awarded in the last three financial years is shown in the following table:
Financial year | Number of bids submitted | Number of rapporteurships awarded |
2015/16 | 86 | 35 |
2016/17 | 87 | 41 |
2017/18 | 66 | 11 |
Metrics for bids submitted prior to this time have not been recorded.
Asked by: Matthew Pennycook (Labour - Greenwich and Woolwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will place in the Library of the House a copy of the Private Finance Initiative contract for the Queen Elizabeth Hospital, Woolwich agreed in 2009 between the Meridian Hospital Company and the South London Healthcare Trust.
Answered by Steve Barclay - Secretary of State for Environment, Food and Rural Affairs
The Private Finance Initiative (PFI) contract for the new Queen Elizabeth Hospital in Woolwich was signed in 1998 between the former Queen Elizabeth Hospitals NHS Trust and the Meridian Hospital Company. Queen Elizabeth Hospitals NHS Trust was dissolved in April 2009 and merged with three other National Health Service trusts to form the South London NHS Trust in their place, the PFI contract transferring to the new trust. The contract transferred to the Lewisham and Greenwich NHS Trust on the dissolution of South London NHS Trust in October 2013. A copy of the contract is attached.